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Abstract
Objective To assess the efficacy of a financial incentive added to routine
specialist pregnancy stop smoking services versus routine care to help
pregnant smokers quit.
Design Phase II therapeutic exploratory single centre, individually
randomised controlled parallel group superiority trial.
Setting One large health board area with a materially deprived, inner
city population in the west of Scotland, United Kingdom.
Participants 612 self reported pregnant smokers in NHS Greater
Glasgow and Clyde who were English speaking, at least 16 years of
age, less than 24 weeks pregnant, and had an exhaled carbon monoxide
breath test result of 7 ppm or more. 306 women were randomised to
incentives and 306 to control.
Interventions The control group received routine care, which was the
offer of a face to face appointment to discuss smoking and cessation
and, for those who attended and set a quit date, the offer of free nicotine
replacement therapy for 10 weeks provided by pharmacy services, and
four, weekly support phone calls. The intervention group received routine
care plus the offer of up to £400 of shopping vouchers: £50 for attending
a face to face appointment and setting a quit date; then another £50 if
at four weeks’ post-quit date exhaled carbonmonoxide confirmed quitting;
a further £100 was provided for continued validated abstinence of
exhaled carbon monoxide after 12 weeks; a final £200 voucher was
provided for validated abstinence of exhaled carbon monoxide at 34-38
weeks’ gestation.
Main outcome measure The primary outcome was cotinine verified
cessation at 34-38 weeks’ gestation through saliva (<14.2 ng/mL) or
urine (<44.7 ng/mL). Secondary outcomes included birth weight,
engagement, and self reported quit at four weeks.
Results Recruitment was extended from 12 to 15 months to achieve
the target sample size. Follow-up continued until September 2013. Of
the 306 women randomised, three controls opted out soon after
enrolment; these women did not want their data to be used, leaving 306
intervention and 303 control group participants in the intention to treat
analysis. No harms of financial incentives were documented. Significantly
more smokers in the incentives group than control group stopped
smoking: 69 (22.5%) versus 26 (8.6%). The relative risk of not smoking
at the end of pregnancy was 2.63 (95% confidence interval 1.73 to 4.01)
P<0.001. The absolute risk difference was 14.0% (95% confidence
interval 8.2% to 19.7%). The number needed to treat (where financial
incentives need to be offered to achieve one extra quitter in late
pregnancy) was 7.2 (95% confidence interval 5.1 to 12.2). The mean
birth weight was 3140 g (SD 600 g) in the incentives group and 3120
(SD 590) g in the control group (P=0.67).
Conclusion This phase II randomised controlled trial provides substantial
evidence for the efficacy of incentives for smoking cessation in
pregnancy; as this was only a single centre trial, incentives should now
be tested in different types of pregnancy cessation services and in
different parts of the United Kingdom.
Trial registration Current Controlled Trials ISRCTN87508788.
Introduction
Of 125 000 spontaneous miscarriages that occur each year in
the United Kingdom,1 25 0001 are associated with smoking
during pregnancy, assuming that 17% of women smoke during
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pregnancy,2 and the relative risk of spontaneous miscarriage
compared with non-smokers is 1.2.3 If causality were accepted,
then with a 20% increase in risk, 5000 miscarriages each year
would be attributable to smoking during pregnancy. Stillbirths
occur at a rate of four for every 1000 live births, and 4-7% are
attributable to smoking during pregnancy,4 accounting for
approximately 180 deaths each year in the United Kingdom.
Infant deaths also occur at a rate of 4 per 1000 live births,5 and
3-5%6 are attributable to smoking during pregnancy—113 infant
deaths each year. In deprived areas, a third of excess stillbirths
and postnatal deaths are explained by smoking during
pregnancy.7 The total annual cost to the UK National Health
Service of smoking during pregnancy is estimated to range
between £8.1m ($12.3m; €10.4m) and £64m for treating the
resulting problems in mothers, and between £12m and £23.5m
in infants (aged 0-12 months).8
Smoking is a major preventable cause of premature maternal
mortality, with lifelong benefits of quitting for children. In
Scotland, 70% of women have at least one baby,9 making
pregnancy an opportunity to help most women quit before their
health is permanently compromised. In 2009, 24% of pregnant
women who attended their first antenatal booking appointment
in Scotland self reported being smokers,10 but only one in 10
used evidence based NHS cessation services, with 3% reporting
abstinence at four weeks after quitting.11 In 2010, the National
Institute for Health and Care Excellence highlighted that
evidence for the effectiveness of financial incentives in a UK
context was needed.8 The latest Cochrane systematic review of
this topic suggests that financial incentives may help pregnant
smokers to stop but that the evidence is limited.12 A recently
completed mixed methods study to inform trial design about
the benefits of incentives13 concluded that financial incentives
may be appropriate to support smoking cessation during
pregnancy, with a lower limit of effectiveness for cessation at
£20 a month and an upper limit of acceptability at £80 a month.
We carried out a single centre, randomised controlled trial in
Glasgow, Scotland, to assess acceptability and begin to explore
efficacy and cost effectiveness of up to £400 of shopping
vouchers added to routine specialist pregnancy NHS “Stop
Smoking Services” to help pregnant smokers quit.
Methods
Design
This was a phase II therapeutic exploratory single centre,
individually randomised controlled parallel group superiority
trial with 1:1 allocation and single blinding of initial primary
outcome assessment. The trial design also included a process
evaluation involving qualitative methods and an economic
analysis. These elements of the trial are reported elsewhere.14
Study population
Although described as a single centre, NHS Greater Glasgow
and Clyde has the largest health board population (1.2m) in the
United Kingdom. It is spread over a wide geographical area
including severely materially deprived post-industrial areas as
well as some more affluent communities. Maternity booking
and antenatal care are provided in both hospital and local
healthcare settings. Delivery (13 844 infants in 201315) takes
place in three major maternity hospitals.
At maternity booking all Glasgow women are asked about
current smoking (at least one cigarette in the preceding week),
and nearly all (97%) consent to a carbon monoxide breath test.16
Self reported smokers are routinely notified to the NHS stop
smoking services. During trial recruitment (December 2011 to
February 2013), in addition to routine care, advisers from the
stop smoking services sought permission to pass women’s
contact details to the trial team. Women were eligible if they
were smokers with an exhaled carbon monoxide level of at least
7 ppm, aged 16 years or more, less than 24 weeks pregnant,
resident in NHS Greater Glasgow and Clyde, and able to
understand and speak English for telephone consent. A carbon
monoxide level of 7 ppm indicates current smoking, although
38% of self reported smokers at maternity booking have levels
below this value,17 often because they have not smoked since
the preceding evening or are light smokers.
Study protocol and interventions
The study followed a published protocol,18which was approved
by West of Scotland research ethics committee 2 on 25 May
2011. A substantial amendment to consent, passed on 15 August
2012, allowed use of residual routine late pregnancy blood
samples to be tested for cotinine (that is, samples collected as
part of routine antenatal care rather than specifically for the
trial). We sought samples for the last 200 participants enrolled.
This provided a check on the primary outcome for this group
of participants and assessed smoking status of those lost to
follow-up.
Enrolment
The stop smoking services aim to contact all smokers notified
to them. Throughout the enrolment period, advisers from the
services discussed the trial with referred women during their
first contact. The contact details of clients who gave permission
were securely passed to the trial team and helpline staff through
the trial database. The helpline (a call centre also commissioned
to provide the NHS Smoking Helpline) contacted women,
confirmed that all selection criteria had been met, enrolled
participants using telephone consent, and conducted concealed
random allocation. All contacts with the helpline were audio
recorded. The trial database and web portal, developed by Echo
Managed Services, allowed the trial team and helpline staff to
enter data at separate sites.
Randomisation and masking
We randomly allocated eligible women to either receive the
offer of up to £400 of shopping vouchers (if they engaged with
services and subsequently quit) added to routine specialist
pregnancy stop smoking services or routine care alone. The
Glasgow Clinical Trials Unit embedded the randomisation in
the trial database using randomised permuted blocks, with a
block length of four, thus facilitating equal distribution of clients
between the interventions. Allocation was concealed from staff
and clients until after consent and recruitment. Helpline staff,
who ascertained the primary outcome, self report of smoking
status in late pregnancy, were blind to allocation status.
Routine specialist pregnancy stop smoking
services
All smokers identified at maternity booking are electronically
notified to stop smoking services. The service’s advisers try to
make contact, and smokers can opt out at this point. The advisers
offer a one hour appointment to discuss smoking and cessation.
This face to face contact is followed by four weekly telephone
support calls and free nicotine replacement therapy from local
pharmacies for 10 weeks. Contact to ascertain smoking status
is attempted at four weeks, 12 weeks (if quit at four weeks) and
one year after the agreed quit date.
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Study groups
The control group was offered routine specialist pregnancy
support by the stop smoking services. The incentives group was
offered the same routine support plus up to £400 of shopping
vouchers (Love2shop) for engaging with stop smoking services
or for quitting during pregnancy, or both. Intervention
participants received £50 of vouchers if they attended their face
to face appointment and set a quit date. As per routine practice,
clients who set a quit date were telephoned by their stop smoking
services adviser four weeks later. Intervention participants who
reported abstinence (that is, had not smoked, even a puff, in the
past two weeks) were visited at home by a research nurse to
confirm smoking status (carbon monoxide breath test result <10
ppm). Confirmed quitters were sent a further £50 voucher.
Twelve weeks after stopping smoking, women in the incentives
group who were quitters at four weeks were contacted by stop
smoking services (routine practice) and, if confirmed to be
abstinent (carbon monoxide breath test result <10 ppm), were
sent a £100 voucher. At a randomly allocated time between 34
and 38 weeks’ gestation all participants were contacted by the
helpline staff to ascertain smoking status. A research nurse
visited self reported quitters to collect a carbonmonoxide level,
and saliva and urine for cotinine estimation. Women in the
incentives group whowere confirmed as abstinent by the carbon
monoxide breath test (<10 ppm) were sent a final £200 voucher.
An external fulfilment house linked to the trial database sent
all vouchers directly to participants.
Data collection
We collected baseline information on carbonmonoxide readings
at maternity booking; self reported smoking status; postcode of
residence; estimated date of delivery; maternal age, height, and
weight; English speaking; the Fagerstrom questionnaire to assess
nicotine addiction19; partner smoking status; parity; and ethnicity.
Data collected at subsequent visits were:
First visit to stop smoking services—date, attended or not, quit
date.
Four week post quit contact—smoked even a puff in past two
weeks, carbon monoxide level for self reported quitters in the
incentives group.
12 week post-quit contact for intervention group quitters
confirmed by carbon monoxide reading at 4 weeks—smoked
even a puff in past four weeks, carbon monoxide level for self
reported quitters in the incentives group.
All participants at 34-38 weeks’ gestation, May 2012 to
September 2013—smoked fewer than five cigarettes in the past
eight weeks, current use of nicotine replacement therapy, carbon
monoxide level, and saliva and urine cotinine level for all self
reported quitters. The main primary outcome analysis assumed
that participants who were lost to follow-up (that is, self reported
smoking status or validation of urine and saliva samples not
obtained) at 34-38 weeks’ gestation had continued to smoke.
To assess if this assumption was valid, we gathered the residual
routine late pregnancy blood samples taken from the last 200
participants enrolled in the trial, collected from NHS
laboratories, and assayed them for cotinine. To minimise losses
to follow-up, particularly among controls, a £25 shopping
voucher was sent to all participants if they provided primary
outcome information and saliva or urine samples as appropriate.
Six month postnatal contact for cotinine confirmed quitters in
late pregnancy, December 2012 to March 2014—still quit or
smoked as few as five cigarettes in total since their quit date (at
least 12 months post-quit).
All participants—date of delivery, birth weight, stillbirth, or
miscarriage (to assess any potential harms).
Outcomes
Table 1⇓ describes the registered and non-registered outcomes.
Non-registered outcomes stillbirth and miscarriage were
described as adverse events to be documented in the protocol
(see table 1⇓).18 We collected gestation used to define preterm
(<37 completed weeks’ gestation) as a confounding variable
for birth weight. Towards the end of the trial, funders (Glasgow
Centre for PopulationHealth) suggested that interventionwomen
may be more likely to take up smoking again soon after their
child was born. Longer term health economic analysis indicated
that this would be important in determining cost per quality
adjusted life year gained. We therefore obtained self report of
current smoking status 12 months after quit date—about six
months after birth—from data routinely collected by stop
smoking services.
Statistical analysis
Assuming a quit rate of 4% in the control group,20 600
participants gave 90% power to detect an increase in quit rate
to 11.4%, or 80% power to detect an increase in quit rate to
10.2%, based on a continuity corrected χ2 test at 5% significance.
We have summarised continuous data as means (standard
deviations) and categorical data as counts (percentages), with t
tests or Fisher’s exact tests used, respectively, to compare
between group comparisons. Smoking status outcomes are
presented as the relative risk (95% confidence interval) of not
smoking. We used logistic regression models to control for
baseline smoking dependence (Fagerstrom questionnaire) and
deprivation status. Analysis of outcomes was by intention to
treat, with 5% statistical significance. Given the definition of
the primary outcome, those who did not provide outcome data
were not eligible to receive incentives and were, by default,
treated as being a smoker at follow-up. There was therefore no
missing data in the primary analysis. Analyses were performed
using SAS (v9.3).
Results
Participant flow and follow-up
Of 3052 self reported smokers identified at maternity booking
between December 2011 and February 2013, 1128 (37%) were
ineligible as their carbon monoxide reading was <7 ppm. A
further 898 (29%) were ineligible, mainly because stop smoking
services were unable to make contact with them. Only 124 of
1150 eligible women contacted (11%) refused permission for
their contact details to be passed to the trial team. Details for
1026 women were therefore transferred (figure⇓). Of this 1026,
after at least three attempts (at times chosen by the client) by
the trial team, 379 (37%) women could not be contacted. In
addition, seven women had miscarried and contact was not
attempted. Of the 640 women contacted, eight were no longer
pregnant and 20 declined to participate. The trial population of
612 pregnant smokers represented 20% of all self reported
smokers (n=3052) who attended for maternity care during the
study period, and 53% of 1150 (1026+124) eligible pregnant
smokers who could be contacted by advisers as part of routine
stop smoking services (figure).
Overall, 306 participants were allocated to the incentives group
and 306 to the control group. Table 2⇓ shows the baseline
characteristics. The two groups were well balanced, except that
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control participants were slightly more nicotine dependent, with
a higher Fagerstrom score.19
Three control participants withdrew from the study immediately
after randomisation and did not wish any of their data to be
included in the statistical analysis. At the primary outcome
assessment call, two intervention participants withdrew from
the study. These participants were included in the statistical
analysis, leaving 306 intervention and 303 control participants
in the final analysis (table 3⇓ and figure).
Primary outcome
Significantly more smokers offered incentives had stopped
smoking at primary outcome assessment: 69 (22.5%) versus 26
(8.6%). The relative risk of not smoking at the end of pregnancy
was 2.63 (95% confidence interval 1.73 to 4.01), P<0.001 (table
3). These results were unaffected after controlling for nicotine
dependence. The absolute risk difference was 14.0% (95%
confidence interval 8.2% to 19.7%). The number needed to treat
was 7.2 (95% confidence interval 5.1 to 12.2).
Forty three (14%) control and 46 (15%) intervention participants
were lost to follow-up at primary outcome assessment.
Secondary outcomes
There was a higher rate of self reported abstinence from smoking
at four weeks after the quit date in the incentives group than
control group (table 4⇓). No between group differences were
seen for engagement with stop smoking services, birth weight,
still birth, miscarriage, or premature birth. Women who were
validated as abstinent by cotinine measurement towards the end
of pregnancy were followed up by telephone postnatally at least
12 months after their original quit date; self report data collected
at this point continued to show a large difference (15% v 4%)
in abstinence rates between the incentives and control groups.
With regard to postnatal relapse, of 26 cotinine validated quitters
in the control group, three could not be contacted and 11 self
reported as relapsed (42% of cotinine validated quitters). Of 69
quitters in the incentives group, four could not be contacted and
18 self reported as relapsed (26% of cotinine validated quitters).
Health economic outcomes are reported in full elsewhere.14
Residual routine blood sample analysis
Analysis of residual routine pregnancy samples that were
available from the last 200 women in the trial indicated that
clients who could not be reached or fully assessed for the
primary outcome were likely to be smokers (table 3). This
validates the assumption made within the main analysis that
participants who were lost to follow-up at the primary outcome
collection point at 34-38 weeks’ gestation were still smoking.
Firstly, for 46 participants in the incentives group, contact could
not be made at 34-38 weeks’ gestation after multiple attempts,
initially by the helpline and then by research nurses after contact
checks. Ten had residual blood samples available, taken for
other purposes at 32-42 weeks’ gestation, and all 10 samples
indicated current smoking when tested for cotinine. Similarly,
three residual samples were available from 43 control
participants, and all indicated current smoking.
Secondly, 30 participants in the incentives group who self
reported as quit at 34-38 weeks’ gestation could never be
reached to allow research nurses to collect a carbon monoxide
sample to validate their self report and to allow the final £200
incentive payment to be sent. Two residual blood samples were
available from this group, and both indicated current smoking.
Likewise, 23 self reported quitters in the control group were
never available for corroboration samples to be collected and
therefore did not receive the £25 incentive payment. No residual
blood samples were available from this group.
Finally, 69 participants in the incentives group had stopped
smoking in late pregnancy, as defined by the Russell Standard21
primary outcome of self report at 34-38 weeks’ gestation
corroborated by measurement of saliva or urine cotinine. From
these participants, 18 had residual blood samples collected for
other reasons in late pregnancy (32-42 weeks’ gestation)
available for cotinine analysis. Eighty per cent (samples from
14 women) confirmed that the participant had quit smoking in
late pregnancy. Similarly, from 26 control participants who quit,
five residual samples were available and four (80%) confirmed
abstinence. This suggests that a small proportion of women to
whom we allocated a positive primary outcome may have
returned to smoking, at least occasionally, within the last 10
weeks of pregnancy, but relapse rates were similar in both
groups and hence this was unlikely to have affected the principal
findings.
More importantly, this additional analysis of residual samples
confirmed that 80% of those who were defined as quitters had
truly quit smoking by late pregnancy and were not “gaming”
the primary outcome assessment.
Discussion
This trial indicates that financial incentives can motivate
pregnant smokers to quit. Significantly more smokers offered
incentives stopped smoking (22.5%) than controls (8.6%). This
study is the largest so far undertaken to test financial incentives
to help pregnant women stop smoking. The four studies (three
in the United States, one in the United Kingdom) included in
the BIBS (benefits of incentives for breastfeeding and smoking
cessation in pregnancy) systematic review 2014 of financial
incentives for smoking cessation in pregnancy13 included 332
participants in total. The combined effect size was a relative
risk for quitting of 2.58 (95% confidence interval 1.63 to 4.07).
This present trial included 612 participants and backs up the
findings of the previous smaller studies, with a relative risk of
2.63 (95% confidence interval 1.73 to 4.01). The absolute risk
difference was 14.0% (95% confidence interval 8.2% to 19.7%),
meaning that the number needed to treat (NNT) was 7.2 (95%
confidence interval 5.1 to 12.2). It should be made clear that
the intervention is the offer of financial incentives if cessation
is achieved. Therefore the NNT is the number of pregnant
smokers who need to be offered financial incentives for each
extra quitter in late pregnancy, not the number who need to be
given financial incentives. This improvement in smoking
cessation is larger than that seen in most behavioural12 or
pharmaceutical22 trials of smoking cessation during pregnancy.
Previous systematic reviews12 highlight that current
recommendations to help smokers quit during pregnancy8 are
not very effective.
Strengths of this study
The trial included a process evaluation and an economic
analysis, the results of which are reported elsewhere.14No harms
were reported, and incentives were acceptable to clients and
healthcare professionals. The short term incremental cost per
quitter at 34-38 weeks’ gestation was £1127, and longer term
cost per quality adjusted life year gained was £482.14 The latter
is well below the UK National Health Service threshold of £20
000.23
One concern was that more women randomised to the control
group (that is, no incentives) might be unavailable for primary
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outcome assessment. This did not happen, as attrition in both
groups was similar. Forty three (14.2%) participants in the
control group and 46 (15·1%) in the incentives group could not
be contacted towards the end of pregnancy. Those lost to
follow-up were assumed to be smokers. We were able to test
this assumption. From the last 200 participants, routine residual
late pregnancy blood samples were available from three control
and 10 intervention participants lost to follow-up. All were
validated as smokers by measurement of cotinine. This supports
the assumption in the analysis that those lost to follow-up were
smokers.
Another issue is the extent to which participants were
representative of the local population. We tested this and results
have been submitted for publication. Trial participants were
representative of all self reported smokers at maternity booking
in Glasgow.
A possible unintended consequence of financial incentives was
that women were untruthful about their smoking status when
asked during the trial, especially at the time of the primary
outcome assessment. Testing for this type of “gaming” was not
the main focus of the trial but was examined to a limited extent.
We found some evidence of women being untruthful about their
smoking status over the telephone. Eighteen participants who
self reported as quit to the helpline subsequently reported as
current smokers when arranging a confirmation visit with the
research nurse. Fifty three others were never available to the
research nurses to collect confirmatory samples. Of these, two
had routine residual late pregnancy blood samples available,
both from intervention participants, which confirmed current
smoking. Secondly, a small number of self reported quitters
were validated as non-smokers by carbon monoxide breath
testing but may have only temporarily abstained, as 18 (16%)
were confirmed as current smokers by testing of saliva or urine
collected by the research nurses at the primary outcome home
visit: six (19%) controls and 12 (15%) intervention participants.
Finally, 4/18 intervention and 1/5 control group quitters in late
pregnancy confirmed by cotinine measurement who also had a
residual routine blood sample taken (table 3), were confirmed
as being positive for cotinine. These women may not have truly
quit smoking in late pregnancy and this issue merits further
research.
Incentives for health behaviour change remain controversial.24
Public perceptions of “paying” individuals to change behaviour
can be negative. However, qualitative elements found that
incentives were acceptable to women and healthcare
professionals.14 In addition, the level of incentive was tested in
a public opinion survey conducted as part of a related study and
was deemed acceptable.13
Weaknesses of this study
This was a phase II study, a therapeutic exploratory trial25
conducted in one centre to explore the efficacy of a new
intervention. Although this was a large phase II trial, a future
definitive trial is clearly needed in more than one centre to
confirm efficacy, cost effectiveness, and generalisability. A
future study needs to consider geographical location and type
of smoking cessation service—for example, specialist pregnancy
service versus generic cessation service and specialist
practitioners versus pharmacy services.26 27 In addition, the
economic analysis included some uncertainty in the results
driven by postnatal relapse. Future studies should more closely
examine outcomes in the postnatal period.
The registered secondary outcome, cessation at four weeks (table
4), available from routine telephone follow-up at four weeks
with the NHS stop smoking services, had high losses to
follow-up—105 (34%) in the incentives group and 171 (56%)
in the control group. This number included 58 (19%)
intervention and 67 (22%) control participants who did not
engage at all with the stop smoking services. Using routinely
collected service data often leads to greater losses to follow-up.
However, overall quit rates at four weeks post-quit date reflected
the same pattern of change in cessation between incentives and
control groups (doubling of quit rate) that was seen in the
primary outcome at 34-38 weeks’ gestation.
Ethical issues related to financial incentives
Smoking during pregnancy remains a major health problem,
resulting in the deaths of an estimated 5000 fetuses and babies
each year in the United Kingdom1-6 and is responsible for tens
of millions of pounds in extra healthcare spending.8The research
question for this study was originally put forward by the
National Institute for Health and Care Excellence.8 Financial
incentives are a complex topic, with several ethical
considerations. However, in addition to effectiveness, an
important outcome is cost effectiveness, particularly the longer
term cost per quality adjusted life year gained, taking account
of any “gaming.” NICE will then decide, using the standard
cut-off of £20 000 per quality adjusted life year gained, if, as
with a new drug or device, this intervention should be
recommended for use by the NHS in the United Kingdom.
In this study, we assessed a new public health intervention
(financial incentives) using clinical trial methods25 often reserved
for new drug products or devices. Most drugs are developed
and used once a disease or condition has manifested and the
patient has sought advice from a doctor. Only a few
interventions, such as vaccines, are able to prevent disease.
Financial incentives to stop smoking could reach smokers who
become pregnant before cigarettes have affected their health.
The reduced mortality and morbidity among offspring will be
multiplied if children subsequently do not take up smoking
because their mother stopped before they were born and thus
lessened the risk that they would grow up in a smoking
household. In the developed world there is now a clear
socioeconomic gradient in smoking, with tobacco use
concentrated among the poorest in society. Receipt of financial
incentives can contribute to needed household income in
advance of the arrival of a baby in low income households. In
addition, stopping smoking reduces inequalities in health
outcomes. If financial incentives are effective and cost effective
they may well have the future potential to sit with vaccines as
an important preventive healthcare intervention strategy.
Conclusions
Smoking in pregnancy remains a leading preventable cause of
maternal and neonatal ill health and death in the United
Kingdom and in most other developed countries. Existing
interventions are not highly effective. This study provides
substantial evidence of a promising and potentially cost effective
new intervention to add to present health service support. The
findings can serve as the basis for future research to include
other UK centres and other healthcare systems.
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What is already known on this topic
Financial incentives have been used in several small trials to help pregnant smokers to quit in the United States, and the National Institute
for Health and Care Excellence has called for research in the United Kingdom to examine cost effectiveness
A recent mixed methods study to inform trial design included a systematic review, which estimated the relative risk of cessation to be
2.58 (95% confidence interval 1.63 to 4.07) with financial incentives
A discrete choice experiment using a MORI poll of the general UK population suggested effective and acceptable levels of incentive
payment lay between £20 and £80 per month
What this study adds
In this single centre therapeutic exploratory UK trial, £400 of voucher incentives paid in instalments over six months helped pregnant
smokers to quit, with no adverse effects and little evidence of “gaming”
Methodology has been developed to run a definitive multicentre trial to examine generalisability and cost effectiveness in the United
Kingdom
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Tables
Table 1| Details of registered and non-registered outcomes
Non-registeredRegisteredOutcome evaluation methodTimingOutcomes
Primary outcome:
— Cotinine verified (saliva <14.2 ng/mL or urine <44.7 ng/mL) self
report of “Have you smoked in the last eight weeks?” If yes “Have
you smoked more than five cigarettes in that time?” Russell
Standard outcome21
34-38 weeks’ gestationQuit in late pregnancy
Secondary outcomes:
——Framework developed to assess costs and benefitsCost effectiveness*
— Attended face to face appointment with NHS stop smoking
services and set a quit date
0-4 weeks after enrolmentEngagement
— Self report through telephone contact from NHS stop smoking
services of “Have you smoked in the last 2 weeks, even a puff?”
4-9 weeks after enrolmentQuit at 4 weeks
 —Self report through telephone contact from NHS stop smoking
services of “Are you still quit?” or “Have you smoked as few as
five cigarettes in total since you quit?”
Approximately 12 months
after quit date
Quit at 6 months after birth
— Patient recordsAt birthBirth weight
 —Patient recordsAt birthStillbirth
 —Patient recordsAt eventMiscarriage
 —Patient recordsAt birthPremature birth (<37 weeks’
gestation)
NHS=National Health Service.
*Reported separately.
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Table 2| Baseline characteristics of trial population by group allocation
Incentives groupControl group
Characteristics
No with missing
dataParticipants (n=306)
No with missing
dataParticipants (n=303)*
Routinely collected maternity booking data
81.62 (0.07)21.63 (0.06)Mean (SD) height (m)
869.82 (16.34)269.37 (16.12)Mean (SD) weight (kg)
826.40 (5.77)226.23 (5.89)Mean (SD) body mass index (kg/m2)
099.7098.7White ethnicity
028.27 (5.77)027.66 (6.07)Mean (SD) maternal age at estimated delivery
(years)
012.27 (2.46)012.62 (2.68)Mean (SD) gestation at booking (weeks)
From routine dataset collected by health board
81 (0-6)91 (0-6)Median (range) previous live births
370 (0-10)500 (0-7)Median (range) previous stillbirth or miscarriage
Routinely collected maternity booking data
SIMD fifth†:
067.0065.01st fifth (most deprived)
016.3017.82nd fifth
09.2010.93rd fifth
03.903.64th fifth
03.602.65th fifth (least deprived)
013.14 (6.41)013.65 (6.34)Mean (SD) baseline carbon monoxide (ppm)
Fagerstrom questionnaire (smoking history
variables):
052.9057.1First cigarette within 5 mins of waking
027.1031.4Difficulty not smoking
059.8065.31st cigarette most difficult to give up
010.5017.1Smoke >20/day
048.0055.1Smoke more in morning
048.7059.7Smoke when ill
059.8066.3Partner smokes
04.85 (2.22)05.32 (2.21)Mean (SD) Fagerstrom score‡
SIMD=Scottish index of multiple deprivation.
*Consent withdrawn post-randomisation for three women.
†Derived from postcode of residence.
‡Uses first six smoking history variables from Fagerstrom questionnaire. Score of ≥5 indicates significant nicotine dependence.
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Table 3| Primary outcome: cotinine verified cessation at 34-38 weeks’ gestation towards end of pregnancy. Values are numbers (percentages)
unless stated otherwise
Relative risk of not
smoking near end
Control groupIncentives group
Data item, data
collection/analysis
Residual blood
cotinine estimation†
Participants
(n=303)‡
Residual blood
cotinine estimation†
Participants
(n=306)*
of pregnancy (95%
CI)
Self reported smoking status
——195 (64.3)—139 (45.4)Smoker:
—3 collected (all
smokers)
43 (14.2)10 collected (all
smokers)
46 (15.1)Lost to follow-up
Non-smoker:
1.84 (1.44 to 2.37)—65 (25.0)—119 (46.1)When smoking status recorded
1.53 (1.28 to 1.84)—108 (35.6)—167 (54.6)When loss to follow-up presumed
not smoking
1.81 (1.41 to 2.35)—65 (21.5)—119 (38.9)When loss to follow-up presumed
smoking
Saliva or urine validated smoking
No cotinine outcome:
——10—8Changed self report to smoker
when phoned to arrange visit
—0 collected232 collected(2 smokers)30Never contactable for carbon
monoxide and cotinine samples
——6—12Carbon monoxide negative,
cotinine positive
Primary outcome
2.63 (1.73 to 4.01)4/5 non-smokers26 (8.6)14/18 non-smokers69 (22.5)Self reported non-smoker and
saliva or urine cotinine negative
*Consent withdrawn post-randomisation (after 12 week stage) for two intervention women (consent given to analyse any data collected).
‡Consent withdrawn post-randomisation for three control women (consent withdrawn to utilise any data collected).
†Residual late pregnancy (between 32 and 42 weeks’ gestation) blood samples collected from last 200 participants and cotinine tested.
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Table 4| Secondary outcomes and data collected. Values are numbers (percentages) unless stated otherwise
P valueRelative risk (95% CI)Control group (n=303)Incentives group (n=306)Variables
0.371.04 (0.96 to 1.13)236 (78)248 (81)Engagement:
0/303 (0)0/306 (0)Missing data
<0.0012.06 (1.60 to 2.66)64 (21)133 (43)Quit at 4 weeks:
171 (56)105 (34)Missing data (no contact)
<0.0013.88 (2.41 to 6.23)12 (4)47 (15)Quit at 6 months after birth:
3/26 (12)4/69 (6)Missing data
0.6720 (−80 to 120)†3102 (590)3140 (600)Mean (SD) birth weight (g):
12/299 (4)10/305 (3)Missing data*
0.290.39 (0.04 to 1.99)5 (1.7)2 (0.7)Stillbirth or miscarriage:
3/299 (1)5/305 (2)Missing data*
0.091.52 (0.95 to 2.39)26 (8.9)40 (13.4)Premature birth:
8/299 (3)7/305 (2)Missing data*
*Including five women (four control, one incentive) excluded from birth analyses as multiple births.
†Difference (95% CI).
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Figure
Flow of participants through study
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